Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1988 Dec;41(12):1249–1255. doi: 10.1136/jcp.41.12.1249

Mechanism of action of intravenous immunoglobulin in immune-mediated cytopenias.

H I Atrah 1, R J Davidson 1
PMCID: PMC1141755  PMID: 3066800

Full text

PDF
1249

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arsura E. L., Bick A., Brunner N. G., Namba T., Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med. 1986 Jul;146(7):1365–1368. [PubMed] [Google Scholar]
  2. Atrah H. I., Crawford R. J. Blood group and response to immunoglobulin in immune thrombocytopenia. Lancet. 1984 Oct 6;2(8406):810–810. doi: 10.1016/s0140-6736(84)90730-x. [DOI] [PubMed] [Google Scholar]
  3. Atrah H. I., Crawford R. J., Gabra G. S., Forwell M. A., Mitchell R., Islam S. I., Ramsay D., Sandilands G. P. Modulation of suppressor T-cells for the treatment of aplastic anaemia. Lancet. 1985 Aug 10;2(8450):339–340. doi: 10.1016/s0140-6736(85)90393-9. [DOI] [PubMed] [Google Scholar]
  4. Atrah H. I., Crawford R. J., Gabra G. S., Mitchell R. Intravenous immunoglobulin therapy for idiopathic thrombocytopenic purpura. Scott Med J. 1986 Oct;31(4):231–233. doi: 10.1177/003693308603100404. [DOI] [PubMed] [Google Scholar]
  5. Atrah H. I., Sandilands G. P. A proposed mechanism of action for ALG and ATG in severe acquired aplastic anaemia. J Clin Lab Immunol. 1988 Feb;25(2):59–62. [PubMed] [Google Scholar]
  6. Atrah H. I., Templeton J. G., Crawford R. J., Gabra G. S., Mitchell R. Passive haemagglutination inhibition for quantitation of red cell associated IgG. J Clin Pathol. 1987 May;40(5):494–499. doi: 10.1136/jcp.40.5.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Augener W., Friedmann B., Brittinger G. Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)? Blut. 1985 Apr;50(4):249–252. doi: 10.1007/BF00320302. [DOI] [PubMed] [Google Scholar]
  8. BERGLUND G. Plasma transfusion treatment of six children with idiopathic thrombocytopenic purpura. Acta Paediatr. 1962 Sep;51:523–528. doi: 10.1111/j.1651-2227.1962.tb06578.x. [DOI] [PubMed] [Google Scholar]
  9. Bacigalupo A., Podestà M., Mingari M. C., Moretta L., Van Lint M. T., Marmont A. Immune suppression of hematopoiesis in aplastic anemia: activity of T-gamma lymphocytes. J Immunol. 1980 Oct;125(4):1449–1453. [PubMed] [Google Scholar]
  10. Baglin T. P., Smith M. P., Boughton B. J. Rapid and complete response of immune thrombocytopenic purpura to a single injection of rhesus anti-D immunoglobulin. Lancet. 1986 Jun 7;1(8493):1329–1330. doi: 10.1016/s0140-6736(86)91251-1. [DOI] [PubMed] [Google Scholar]
  11. Ball S., Zuiable A., Roter B. L., Hegde U. M. Changes in platelet immunoprotein levels during therapy in adult immune thrombocytopenia. Br J Haematol. 1985 Aug;60(4):631–633. doi: 10.1111/j.1365-2141.1985.tb07466.x. [DOI] [PubMed] [Google Scholar]
  12. Bierling P., Farcet J. P., Duedari N., Rochant H. Increase-platelet-associated IgG in patient on high-dose gammaglobulin for autoimmune thrombocytopenic purpura. Lancet. 1982 Aug 14;2(8294):388–388. doi: 10.1016/s0140-6736(82)90580-3. [DOI] [PubMed] [Google Scholar]
  13. Budde U., Auch D., Niese D., Schäfer G., Reske S. N., Schmidt R. E. Reticuloendothelial system Fc-receptor function in patients with immune thrombocytopenia after treatment with high dose intravenous immunoglobulin. Scand J Haematol. 1986 Aug;37(2):125–129. doi: 10.1111/j.1600-0609.1986.tb01785.x. [DOI] [PubMed] [Google Scholar]
  14. Bussel J. B., Hilgartner M. W. The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease. Br J Haematol. 1984 Jan;56(1):1–7. doi: 10.1111/j.1365-2141.1984.tb01266.x. [DOI] [PubMed] [Google Scholar]
  15. Bussel J. B., Kimberly R. P., Inman R. D., Schulman I., Cunningham-Rundles C., Cheung N., Smithwick E. M., O'Malley J., Barandun S., Hilgartner M. W. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood. 1983 Aug;62(2):480–486. [PubMed] [Google Scholar]
  16. Bussel J. B., Pham L. C. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang. 1987;52(3):206–211. doi: 10.1111/j.1423-0410.1987.tb03029.x. [DOI] [PubMed] [Google Scholar]
  17. Bussel J. B., Schulman I., Hilgartner M. W., Barandun S. Intravenous use of gammaglobulin in the treatment of chronic immune thrombocytopenic purpura as a means to defer splenectomy. J Pediatr. 1983 Oct;103(4):651–654. doi: 10.1016/s0022-3476(83)80608-8. [DOI] [PubMed] [Google Scholar]
  18. Clauvel J. P., Vainchenker W., Herrera A., Dellagi K., Vinci G., Tabilio A., Lacombe C. Treatment of pure red cell aplasia by high dose intravenous immunoglobulins. Br J Haematol. 1983 Oct;55(2):380–382. doi: 10.1111/j.1365-2141.1983.tb01260.x. [DOI] [PubMed] [Google Scholar]
  19. Cocker J. E., Templeton G., Peel M. G., Crawford R. J., Crichton W. B., Sandilands G. P. Lymphocyte Fc gamma-receptor blocking antibodies in intravenous gammaglobulin preparations. J Clin Lab Immunol. 1987 Feb;22(2):85–90. [PubMed] [Google Scholar]
  20. Cohen L., Sharp S., Kulczycki A., Jr Human monocytes, B lymphocytes, and non-B lymphocytes each have structurally unique Fc gamma receptors. J Immunol. 1983 Jul;131(1):378–383. [PubMed] [Google Scholar]
  21. Cross A. S., Alving B. M., Sadoff J. C., Baldwin P., Terebelo H., Tang D. Intravenous immune globulin: a cautionary note. Lancet. 1984 Apr 21;1(8382):912–912. doi: 10.1016/s0140-6736(84)91376-x. [DOI] [PubMed] [Google Scholar]
  22. Dammacco F., Iodice G., Campobasso N. Treatment of adult patients with idiopathic thrombocytopenic purpura with intravenous immunoglobulin: effects on circulating T cell subsets and PWM-induced antibody synthesis in vitro. Br J Haematol. 1986 Jan;62(1):125–135. doi: 10.1111/j.1365-2141.1986.tb02908.x. [DOI] [PubMed] [Google Scholar]
  23. Delfraissy J. F., Tchernia G., Laurian Y., Wallon C., Galanaud P., Dormont J. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol. 1985 Jun;60(2):315–322. doi: 10.1111/j.1365-2141.1985.tb07417.x. [DOI] [PubMed] [Google Scholar]
  24. Doskocil M., Med M., Vimmer T. Musculus rectus femoris--zacátecní slacha, její funkcní význam. Acta Chir Orthop Traumatol Cech. 1987 Apr;54(2):99–107. [PubMed] [Google Scholar]
  25. Durandy A., Fischer A., Griscelli C. Dysfunctions of pokeweed mitogen-stimulated T and B lymphocyte responses induced by gammaglobulin therapy. J Clin Invest. 1981 Mar;67(3):867–877. doi: 10.1172/JCI110104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Emilia G., Sacchi S., Torelli G., Selleri L., Torelli U. Low-dose intravenous pepsin-treated gammaglobulin for idiopathic thrombocytopenic purpura in adults. Br J Haematol. 1984 Dec;58(4):761–762. doi: 10.1111/j.1365-2141.1984.tb06123.x. [DOI] [PubMed] [Google Scholar]
  27. Engelhard D., Waner J. L., Kapoor N., Good R. A. Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia. J Pediatr. 1986 Jan;108(1):77–81. doi: 10.1016/s0022-3476(86)80772-7. [DOI] [PubMed] [Google Scholar]
  28. FINKELSTEIN M. S., UHR J. W. SPECIFIC INHIBITION OF ANTIBODY FORMATION BY PASSIVELY ADMINISTERED 19S AND 7S ANTIBODY. Science. 1964 Oct 2;146(3640):67–69. doi: 10.1126/science.146.3640.67. [DOI] [PubMed] [Google Scholar]
  29. Fehr J., Hofmann V., Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med. 1982 May 27;306(21):1254–1258. doi: 10.1056/NEJM198205273062102. [DOI] [PubMed] [Google Scholar]
  30. Forwell M., Gray K. G., MacSween R. N., Peel M. G., Madhok R., Forbes C. D., Harvey J. A., Roberts J., Ferrell L., Sandilands G. P. Immunosuppression following alloantigen exposure: a role for lymphocyte Fc gamma-receptor blocking antibodies. J Clin Lab Immunol. 1986 Feb;19(2):53–57. [PubMed] [Google Scholar]
  31. Gilhus N. E., Matre R. Fc gamma receptors and HLA-DR antigens on thymus cells in myasthenia gravis. J Neuroimmunol. 1986 Jan;10(3):271–278. doi: 10.1016/0165-5728(86)90107-4. [DOI] [PubMed] [Google Scholar]
  32. Gross B., Haessig A., Luescher E. F., Nydegger U. E. Monomeric IgG preparations for intravenous use inhibit platelet stimulation by polymeric IgG. Br J Haematol. 1983 Feb;53(2):289–299. doi: 10.1111/j.1365-2141.1983.tb02023.x. [DOI] [PubMed] [Google Scholar]
  33. Imbach P., Barandun S., Baumgartner C., Hirt A., Hofer F., Wagner H. P. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981 Feb;36(1):81–86. [PubMed] [Google Scholar]
  34. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., Rossi E., Schöni M., Vest M., Wagner H. P. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981 Jun 6;1(8232):1228–1231. doi: 10.1016/s0140-6736(81)92400-4. [DOI] [PubMed] [Google Scholar]
  35. Imbach P., Jungi T. W. Possible mechanisms of intravenous immunoglobulin treatment in childhood idiopathic thrombocytopenic purpura (ITP). Blut. 1983 Mar;46(3):117–124. doi: 10.1007/BF00320269. [DOI] [PubMed] [Google Scholar]
  36. Jerne N. K. Towards a network theory of the immune system. Ann Immunol (Paris) 1974 Jan;125C(1-2):373–389. [PubMed] [Google Scholar]
  37. Kawada K., Terasaki P. I. Evidence for immunosuppression by high-dose gammaglobulin. Exp Hematol. 1987 Feb;15(2):133–136. [PubMed] [Google Scholar]
  38. Kay H. D., Bonnard G. D., West W. H., Herberman R. B. A functional comparison of human Fc-receptor-bearing lymphocytes active in natural cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol. 1977 Jun;118(6):2058–2066. [PubMed] [Google Scholar]
  39. Khayat D., Geffrier C., Yoon S., Scigliano E., Soubrane C., Weil M., Unkeless J. C., Jacquillat C. Soluble circulating Fc gamma receptors in human serum. A new ELISA assay for specific and quantitative detection. J Immunol Methods. 1987 Jun 26;100(1-2):235–241. doi: 10.1016/0022-1759(87)90194-3. [DOI] [PubMed] [Google Scholar]
  40. Kimberly R. P., Salmon J. E., Bussel J. B., Crow M. K., Hilgartner M. W. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol. 1984 Feb;132(2):745–750. [PubMed] [Google Scholar]
  41. Kurata Y., Tsubakio T., Yonezawa T., Tarui S. High-dose gammaglobulin therapy for idiopathic thrombocytopenic purpura in adults. Acta Haematol. 1983;69(6):391–397. doi: 10.1159/000206927. [DOI] [PubMed] [Google Scholar]
  42. Kurlander R. J. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest. 1980 Oct;66(4):773–781. doi: 10.1172/JCI109915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Latif Z. A., Fletcher M. A. Immunochemical studies of infectious mononucleosis--XI. comparison of heterophile antibody inhibitors from the erythrocyte membranes of four mammalian species. Mol Immunol. 1983 Jan;20(1):1–10. doi: 10.1016/0161-5890(83)90099-8. [DOI] [PubMed] [Google Scholar]
  44. Lucas G. S., Jobbins K., Bloom A. L. Intravenous immunoglobulin and blood group antibodies. Lancet. 1987 Sep 26;2(8561):742–742. doi: 10.1016/s0140-6736(87)91100-7. [DOI] [PubMed] [Google Scholar]
  45. Macey M. G., Sangster J. M., Newland A. C. Blood group and response to high dose IgG. Lancet. 1985 Jun 22;1(8443):1445–1445. doi: 10.1016/s0140-6736(85)91869-0. [DOI] [PubMed] [Google Scholar]
  46. Minchinton R. M., McGrath K. Binding and antibody blocking effects of intravenous IgG preparation on peripheral blood cells. Clin Lab Haematol. 1987;9(1):49–58. doi: 10.1111/j.1365-2257.1987.tb01381.x. [DOI] [PubMed] [Google Scholar]
  47. Morgenstern G. R., Measday B., Hegde U. M. Autoimmune thrombocytopenia in pregnancy: new approach to management. Br Med J (Clin Res Ed) 1983 Aug 27;287(6392):584–584. doi: 10.1136/bmj.287.6392.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Newland A. C., Treleaven J. G., Minchinton R. M., Waters A. H. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet. 1983 Jan 15;1(8316):84–87. doi: 10.1016/s0140-6736(83)91738-5. [DOI] [PubMed] [Google Scholar]
  49. Reiquam C. W., Prosper J. C. Fresh plasma transfusions in the treatment of acute thrombocytopenic purpura. J Pediatr. 1966 Jun;68(6):880–884. doi: 10.1016/s0022-3476(66)80205-6. [DOI] [PubMed] [Google Scholar]
  50. Rewald E. Repeated low doses of anti-rhesus gammaglobulin in aplastic anaemia. Lancet. 1987 Oct 3;2(8562):795–795. doi: 10.1016/s0140-6736(87)92522-0. [DOI] [PubMed] [Google Scholar]
  51. Riggio R. R., Cheigh J. S., Stenzel K. H., Suthanthiran M., Chami J., Saal S. D., Sullivan J. F., Haschemeyer R., Tapia L., Stubenbord W. T. Kidney transplantation; use of gamma globulin as an immunosuppressive agent. N Y State J Med. 1980 Sep;80(10):1561–1563. [PubMed] [Google Scholar]
  52. Roll J., Boyer J. L., Barry D., Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med. 1983 Jan 6;308(1):1–7. doi: 10.1056/NEJM198301063080101. [DOI] [PubMed] [Google Scholar]
  53. Römer J., Morgenthaler J. J., Scherz R., Skvaril F. Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content. Vox Sang. 1982 Feb;42(2):62–73. doi: 10.1159/000460850. [DOI] [PubMed] [Google Scholar]
  54. Salama A., Kiefel V., Amberg R., Mueller-Eckhardt C. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D). Blut. 1984 Jul;49(1):29–35. doi: 10.1007/BF00320381. [DOI] [PubMed] [Google Scholar]
  55. Salama A., Mueller-Eckhardt C., Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet. 1983 Jul 23;2(8343):193–195. doi: 10.1016/s0140-6736(83)90175-7. [DOI] [PubMed] [Google Scholar]
  56. Saleh M. N., Court W. S., LoBuglio A. F. In vitro effects of gammaglobulin (IgG) on human monocyte Fc receptor function. I. Effect on monocyte membrane-associated IgG and Fc receptor-dependent binding of antibody-coated platelets. Am J Hematol. 1986 Nov;23(3):197–207. doi: 10.1002/ajh.2830230303. [DOI] [PubMed] [Google Scholar]
  57. Salmon J. E., Kapur S., Kimberly R. P. Gammaglobulin for intravenous use induces an Fc gamma receptor-specific decrement in phagocytosis by blood monocytes. Clin Immunol Immunopathol. 1987 Apr;43(1):23–33. doi: 10.1016/0090-1229(87)90154-1. [DOI] [PubMed] [Google Scholar]
  58. Sandilands G. P., Atrah H. I., Templeton G., Cocker J. E., Lucie N., Crawford R. J., MacSween R. N. In vivo and in vitro blocking of human lymphocyte Fc gamma-receptors by intravenous gammaglobulin. J Clin Lab Immunol. 1987 Jul;23(3):109–115. [PubMed] [Google Scholar]
  59. Schmidt B., Forster J. Increased platelet-associated IgG in child on high-dose gammaglobulin for idiopathic thrombocytopenic purpura. Lancet. 1982 Jul 3;2(8288):39–40. doi: 10.1016/s0140-6736(82)91168-0. [DOI] [PubMed] [Google Scholar]
  60. Schmidt R. E., Budde U., Bröschen-Zywietz C., Schäfer G., Mueller-Eckhardt C. High dose gammaglobulin therapy in adults with idiopathic thrombocytopenic purpura (ITP). Clinical effects. Blut. 1984 Jan;48(1):19–25. doi: 10.1007/BF00320713. [DOI] [PubMed] [Google Scholar]
  61. Schmidt R. E., Budde U., Schäfer G., Stroehmann I. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet. 1981 Aug 29;2(8244):475–476. doi: 10.1016/s0140-6736(81)90810-2. [DOI] [PubMed] [Google Scholar]
  62. Solal-Celigny P., Bernard J. F., Herrera A., Boivin P. Treatment of adult autoimmune thrombocytopenic purpura with high-dose intravenous plasmin-cleaved gammaglobulins. Scand J Haematol. 1983 Jul;31(1):39–44. doi: 10.1111/j.1600-0609.1983.tb02134.x. [DOI] [PubMed] [Google Scholar]
  63. Stiehm E. R., Ashida E., Kim K. S., Winston D. J., Haas A., Gale R. P. Intravenous immunoglobulins as therapeutic agents. Ann Intern Med. 1987 Sep;107(3):367–382. doi: 10.7326/0003-4819-107-2-367. [DOI] [PubMed] [Google Scholar]
  64. Stohl W. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J Immunol. 1986 Jun 15;136(12):4407–4413. [PubMed] [Google Scholar]
  65. Sultan Y., Kazatchkine M. D., Maisonneuve P., Nydegger U. E. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984 Oct 6;2(8406):765–768. doi: 10.1016/s0140-6736(84)90701-3. [DOI] [PubMed] [Google Scholar]
  66. Thomas E. D., Storb R. Acquired severe aplastic anemia: progress and perplexity. Blood. 1984 Aug;64(2):325–328. [PubMed] [Google Scholar]
  67. Tovo P. A., Miniero R., Fiandino G., Saracco P., Messina M. Fc-depleted vs intact intravenous immunoglobulin in chronic ITP. J Pediatr. 1984 Oct;105(4):676–677. doi: 10.1016/s0022-3476(84)80455-2. [DOI] [PubMed] [Google Scholar]
  68. Tsubakio T., Kurata Y., Katagiri S., Kanakura Y., Tamaki T., Kuyama J., Kanayama Y., Yonezawa T., Tarui S. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol. 1983 Sep;53(3):697–702. [PMC free article] [PubMed] [Google Scholar]
  69. Uchida T., Yui T., Umezu H., Kariyone S. Prolongation of platelet survival in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. Thromb Haemost. 1984 Feb 28;51(1):65–66. [PubMed] [Google Scholar]
  70. Vaughn M., Taylor M., Mohanakumar T. Characterization of human IgG Fc receptors. J Immunol. 1985 Dec;135(6):4059–4065. [PubMed] [Google Scholar]
  71. Winiarski J., Kreuger A., Ejderhamn J., Holm G. High dose intravenous IgG reduces platelet associated immunoglobulins and complement in idiopathic thrombocytopenic purpura. Scand J Haematol. 1983 Oct;31(4):342–348. doi: 10.1111/j.1600-0609.1983.tb00662.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES